Skip to main content
November 04

November 04, 2026
Bad Homburg, Germany

Quarterly Financial Report Q3 2026

Conference Call Q3 2026

November 04, 2026
Bad Homburg, Germany

Conference Call Q3 2026

Conference Call Q2 2026

August 05, 2026
Bad Homburg, Germany

Conference Call Q2 2026

August 05

August 05, 2026
Bad Homburg, Germany

Half-year Financial Report H1 2026

May 06

May 06, 2026
Bad Homburg, Germany

Quarterly Financial Report Q1 2026

Conference Call Full Year Results 2025

February 25, 2026
Bad Homburg, Germany

Conference Call Full Year Results 2025

Next event

Conference Call Q1 2026

May 06, 2026
Bad Homburg, Germany

Conference Call Q1 2026

  • Sale in two independent steps simplifies and accelerates divestment of Vamed’s Austrian activities
  • Fresenius and Porr signed an agreement today on the sale of Austrian project business and the thermal spas operations of VAMED Vitality World
  • In-depth talks ongoing with Strabag on sale of Vienna General Hospital (AKH Wien) operations business 

 

The healthcare group Fresenius is accelerating and simplifying the divestment of Vamed's Austrian activities by a sale in two independent steps. The original agreement to sell to an Austrian consortium consisting of the construction companies Porr and Strabag has now been replaced by a direct contract with Porr for the sale of the Austrian project business and the thermal spas operations of VAMED Vitality World. The new agreement is subject to regulatory approval. 

 

In-depth talks are also ongoing with Strabag regarding remaining parts of Vamed's Austrian activities – primarily the operations business of the Vienna General Hospital (AKH Wien). 

 

The sale of the Austrian activities is another step in Fresenius' structured exit from its investment company Vamed, enabling Fresenius to further increase focus on the ongoing progress of Fresenius Kabi and Fresenius Helios in line with #FutureFresenius. 

Quarterly Financial Report Q3 2025

November 05, 2025
Bad Homburg, Germany

Quarterly Financial Report Q3 2025

Subscribe to